From Wikipedia, the free encyclopedia
  (Redirected from Para-fluorofentanyl)
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
Legal status
CAS Number 90736-23-5 YesY
ATC code None
PubChem CID: 62300
ChemSpider 56096 YesY
ChEBI CHEBI:61074 YesY
Chemical data
Formula C22H27FN2O
Molecular mass 354.461 g/mol
 YesY (what is this?)  (verify)

Parafluorofentanyl (4-Fluorofentanyl) is an opioid analgesic being an analogue of fentanyl developed by Janssen Pharmaceutica in the 1960s.[1]

4-Fluorofentanyl was sold briefly on the US black market in the early 1980s,[citation needed] before the introduction of the Federal Analog Act which for the first time attempted to control entire families of drugs based on their structural similarity rather than scheduling each drug individually as they appeared.[2] 4-Fluorofentanyl is made with the same synthetic route as fentanyl, but by substituting para-fluoroaniline for aniline in the synthesis.[3]

Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.[4]

See also[edit]


  1. ^ US patent 3164600 
  2. ^ Henderson, G. L. (1988). "Designer Drugs: Past History and Future Prospects". Journal of Forensic Sciences 33 (2): 569–575. PMID 3286815. 
  3. ^ Ulens, C.; Van Boven, M.; Daenens, P.; Tytgat, J. (2000). "Interaction of p-Fluorofentanyl on Cloned Human Opioid Receptors and Exploration of the Role of Trp-318 and His-319 in μ-Opioid Receptor Selectivity" (pdf). The Journal of Pharmacology and Experimental Therapeutics 294 (3): 1024–1033. PMID 10945855. 
  4. ^ Jane Mounteney, Isabelle Giraudon, Gleb Denissov, Paul Griffiths (July 2015). "Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe.". The international journal of drug policy. 26 (7): 626–631. doi:10.1016/j.drugpo.2015.04.003. PMID 25976511.